|
CN104994873B
(zh)
*
|
2012-10-04 |
2017-12-22 |
达纳－法伯癌症研究所公司 |
人单克隆抗‑pd‑l1抗体和使用方法
|
|
CA2933707A1
(en)
|
2013-12-20 |
2015-06-25 |
Fred Hutchinson Cancer Research Center |
Tagged chimeric effector molecules and receptors thereof
|
|
CA2949998A1
(en)
|
2014-05-28 |
2015-12-03 |
Agenus Inc. |
Anti-gitr antibodies and methods of use thereof
|
|
PT3151921T
(pt)
|
2014-06-06 |
2019-11-21 |
Bristol Myers Squibb Co |
Anticorpos contra recetor do fator de necrose tumoral induzido por glicocorticoide e utilizações dos mesmos
|
|
IL252295B2
(en)
|
2014-12-19 |
2023-10-01 |
Dana Farber Cancer Inst Inc |
Chimeric antigen receptors and methods of using them
|
|
EP3288570A4
(en)
|
2015-04-29 |
2018-11-21 |
Fred Hutchinson Cancer Research Center |
Modified stem cells and uses thereof
|
|
ES2810856T3
(es)
|
2015-06-03 |
2021-03-09 |
Bristol Myers Squibb Co |
Anticuerpos ANTI-GITR para diagnóstico de cáncer
|
|
AU2016297249B2
(en)
|
2015-07-23 |
2020-11-12 |
Inhibrx Biosciences, Inc. |
Multivalent and multispecific GITR-binding fusion proteins
|
|
BR112018010172A2
(pt)
|
2015-11-19 |
2018-11-21 |
Bristol Myers Squibb Co |
anticorpos contra receptor de fator de necrose de tumor induzido por glicocorticoide (gitr) e usos dos mesmos
|
|
CN108883173B
(zh)
|
2015-12-02 |
2022-09-06 |
阿吉纳斯公司 |
抗体和其使用方法
|
|
EP3452082A1
(en)
|
2016-05-04 |
2019-03-13 |
Fred Hutchinson Cancer Research Center |
Cell-based neoantigen vaccines and uses thereof
|
|
AU2017278193B9
(en)
|
2016-06-10 |
2024-02-01 |
Regeneron Pharmaceuticals, Inc. |
Anti-GITR antibodies and uses thereof
|
|
CN116903741A
(zh)
|
2016-06-20 |
2023-10-20 |
科马布有限公司 |
特异性结合于pd-l1的抗体或其抗原结合片段及其用途
|
|
EP4512829A3
(en)
|
2016-07-14 |
2025-06-11 |
Bristol-Myers Squibb Company |
Antibodies against tim3 and uses thereof
|
|
KR102534568B1
(ko)
*
|
2016-07-22 |
2023-05-18 |
다나-파버 캔서 인스티튜트 인크. |
글루코코르티코이드-유도된 종양 괴사 인자 수용체 (gitr) 항체 및 이의 이용 방법
|
|
BR112019005633A8
(pt)
|
2016-09-23 |
2023-04-11 |
Hutchinson Fred Cancer Res |
Tcrs específicos para antigênio ha-1 de histocompatibilidade (h) menor e usos dos mesmos
|
|
WO2018071913A2
(en)
|
2016-10-14 |
2018-04-19 |
Dana-Farber Cancer Institute, Inc. |
Modular tetrameric bispecific antibody platform
|
|
WO2018089628A1
(en)
|
2016-11-09 |
2018-05-17 |
Agenus Inc. |
Anti-ox40 antibodies, anti-gitr antibodies, and methods of use thereof
|
|
CA3054885A1
(en)
*
|
2017-03-03 |
2018-09-07 |
Rinat Neuroscience Corp. |
Anti-gitr antibodies and methods of use thereof
|
|
SG11201908527SA
(en)
|
2017-03-15 |
2019-10-30 |
Hutchinson Fred Cancer Res |
High affinity mage-a1-specific tcrs and uses thereof
|
|
AR111651A1
(es)
|
2017-04-28 |
2019-08-07 |
Novartis Ag |
Conjugados de anticuerpos que comprenden agonistas del receptor de tipo toll y terapias de combinación
|
|
KR20200006115A
(ko)
|
2017-05-16 |
2020-01-17 |
브리스톨-마이어스 스큅 컴퍼니 |
항-gitr 효능제 항체에 의한 암의 치료
|
|
AU2018271991B2
(en)
|
2017-05-24 |
2024-07-11 |
Effector Therapeutics, Inc. |
Compositions and methods for an improved antitumor immune response
|
|
WO2018229715A1
(en)
|
2017-06-16 |
2018-12-20 |
Novartis Ag |
Compositions comprising anti-cd32b antibodies and methods of use thereof
|
|
CN110785187B
(zh)
|
2017-06-22 |
2024-04-05 |
诺华股份有限公司 |
针对cd73的抗体分子及其用途
|
|
WO2018235056A1
(en)
|
2017-06-22 |
2018-12-27 |
Novartis Ag |
Il-1beta binding antibodies for use in treating cancer
|
|
TW201904993A
(zh)
|
2017-06-22 |
2019-02-01 |
瑞士商諾華公司 |
IL-1β 結合抗體之用途
|
|
US20200172628A1
(en)
|
2017-06-22 |
2020-06-04 |
Novartis Ag |
Antibody molecules to cd73 and uses thereof
|
|
US20200223924A1
(en)
|
2017-06-27 |
2020-07-16 |
Novartis Ag |
Dosage regimens for anti-tim-3 antibodies and uses thereof
|
|
CN110461874B
(zh)
|
2017-06-30 |
2022-04-12 |
江苏恒瑞医药股份有限公司 |
抗gitr抗体、其抗原结合片段及其医药用途
|
|
IL319798A
(en)
|
2017-07-20 |
2025-05-01 |
Novartis Ag |
ANTI-LAG-3 Antibody Dosage Regimens and Their Uses
|
|
WO2019033057A1
(en)
|
2017-08-11 |
2019-02-14 |
Fred Hutchinson Cancer Research Center |
SPECIFIC BRAF TCR AND USES THEREOF
|
|
US20200262894A1
(en)
|
2017-09-06 |
2020-08-20 |
Fred Hutchinson Cancer Research Center |
Strep-tag specific binding proteins and uses thereof
|
|
AU2018327225A1
(en)
|
2017-09-06 |
2020-02-27 |
Fred Hutchinson Cancer Center |
Strep-tag specific chimeric receptors and uses thereof
|
|
WO2019051135A1
(en)
|
2017-09-06 |
2019-03-14 |
Fred Hutchinson Cancer Research Center |
METHODS FOR IMPROVING ADOPTIVE CELL THERAPY
|
|
US20210069241A1
(en)
|
2017-10-20 |
2021-03-11 |
Fred Hutchinson Cancer Research Center |
Compositions and methods of immunotherapy targeting tigit and/or cd112r or comprising cd226 overexpression
|
|
US20210040205A1
(en)
|
2017-10-25 |
2021-02-11 |
Novartis Ag |
Antibodies targeting cd32b and methods of use thereof
|
|
MX2020004756A
(es)
|
2017-11-16 |
2020-08-20 |
Novartis Ag |
Terapias de combinacion.
|
|
WO2019109047A1
(en)
|
2017-12-01 |
2019-06-06 |
Fred Hutchinson Cancer Research Center |
Binding proteins specific for 5t4 and uses thereof
|
|
WO2019140278A1
(en)
|
2018-01-11 |
2019-07-18 |
Fred Hutchinson Cancer Research Center |
Immunotherapy targeting core binding factor antigens
|
|
WO2019140229A1
(en)
|
2018-01-12 |
2019-07-18 |
Bristol-Myers Squibb Company |
Antibodies against tim3 and uses thereof
|
|
BR112020016330A8
(pt)
|
2018-02-12 |
2023-04-18 |
Hutchinson Fred Cancer Res |
Receptores de células t específicas a ciclina a1 e usos dos mesmos
|
|
CA3091138A1
(en)
|
2018-02-26 |
2019-08-29 |
Fred Hutchinson Cancer Research Center |
Compositions and methods for cellular immunotherapy
|
|
EP3765070A4
(en)
|
2018-03-14 |
2021-12-15 |
Dana-Farber Cancer Institute, Inc. |
SPECIFICALLY MODIFIED CELLS, T-LYMPHOCYTE IMMUNE MODULATION ANTIBODIES AND THEIR USE PROCEDURES
|
|
KR102874694B1
(ko)
|
2018-03-21 |
2025-10-23 |
파이브 프라임 테라퓨틱스, 인크. |
산성 pH에서 VISTA에 결합하는 항체
|
|
JP7611700B2
(ja)
|
2018-03-27 |
2025-01-10 |
ブリストル－マイヤーズ スクイブ カンパニー |
紫外線シグナルを使用した力価のリアルタイムモニタリング
|
|
US20210147547A1
(en)
|
2018-04-13 |
2021-05-20 |
Novartis Ag |
Dosage Regimens For Anti-Pd-L1 Antibodies And Uses Thereof
|
|
AR126019A1
(es)
|
2018-05-30 |
2023-09-06 |
Novartis Ag |
Anticuerpos frente a entpd2, terapias de combinación y métodos de uso de los anticuerpos y las terapias de combinación
|
|
CA3106380A1
(en)
|
2018-05-31 |
2019-12-05 |
Glyconex Inc. |
Therapeutic antibodies
|
|
US20210214459A1
(en)
|
2018-05-31 |
2021-07-15 |
Novartis Ag |
Antibody molecules to cd73 and uses thereof
|
|
JP2021528393A
(ja)
|
2018-06-15 |
2021-10-21 |
フラグシップ パイオニアリング イノベーションズ ブイ，インコーポレーテッド |
後細胞シグナル伝達因子の調節による免疫活性の上昇
|
|
EP3820904A2
(en)
|
2018-07-09 |
2021-05-19 |
Five Prime Therapeutics, Inc. |
Antibodies binding to ilt4
|
|
AR116109A1
(es)
|
2018-07-10 |
2021-03-31 |
Novartis Ag |
Derivados de 3-(5-amino-1-oxoisoindolin-2-il)piperidina-2,6-diona y usos de los mismos
|
|
BR112020026947B1
(pt)
|
2018-07-10 |
2022-11-22 |
Novartis Ag |
Derivados de 3-(5-hidróxi-1-oxoisoindolin-2-il)piperidina-2,6-diona, e composição farmacêutica
|
|
CN121203021A
(zh)
|
2018-07-11 |
2025-12-26 |
戊瑞治疗有限公司 |
在酸性pH下结合至VISTA的抗体
|
|
WO2020018964A1
(en)
|
2018-07-20 |
2020-01-23 |
Fred Hutchinson Cancer Research Center |
Compositions and methods for controlled expression of antigen-specific receptors
|
|
WO2020021465A1
(en)
|
2018-07-25 |
2020-01-30 |
Advanced Accelerator Applications (Italy) S.R.L. |
Method of treatment of neuroendocrine tumors
|
|
KR20210049119A
(ko)
|
2018-08-22 |
2021-05-04 |
프레드 헛친슨 켄서 리서치 센터 |
Kras 또는 her2 항원을 표적으로 하는 면역요법
|
|
US20240165232A1
(en)
|
2018-09-24 |
2024-05-23 |
Fred Hutchinson Cancer Research Center |
Chimeric receptor proteins and uses thereof
|
|
WO2020089811A1
(en)
|
2018-10-31 |
2020-05-07 |
Novartis Ag |
Dc-sign antibody drug conjugates
|
|
KR20210102231A
(ko)
|
2018-11-09 |
2021-08-19 |
프레드 헛친슨 켄서 리서치 센터 |
메소텔린에 특이적인 t 세포 수용체 및 면역요법에서의 그의 용도
|
|
CN111234018A
(zh)
*
|
2018-11-29 |
2020-06-05 |
上海开拓者生物医药有限公司 |
全人抗gitr抗体及其制备方法
|
|
JP7498714B2
(ja)
|
2018-12-19 |
2024-06-12 |
ヒューマブス・バイオメッド・ソシエテ・アノニム |
Ｂ型肝炎ウイルスを中和する抗体およびその使用
|
|
BR112021011874A2
(pt)
|
2018-12-20 |
2021-09-08 |
Novartis Ag |
Regime de dosagem e combinação farmacêutica compreendendo derivados de 3-(1-oxoisoindolin-2-il)piperidina-2,6-diona
|
|
WO2020128613A1
(en)
|
2018-12-21 |
2020-06-25 |
Novartis Ag |
Use of il-1beta binding antibodies
|
|
CA3119584A1
(en)
|
2018-12-21 |
2020-06-25 |
Novartis Ag |
Use of il-1 beta antibodies in the treatment or prevention of myelodysplastic syndrome
|
|
CA3119582A1
(en)
|
2018-12-21 |
2020-06-25 |
Novartis Ag |
Use of il-1.beta. binding antibodies
|
|
WO2020128637A1
(en)
|
2018-12-21 |
2020-06-25 |
Novartis Ag |
Use of il-1 binding antibodies in the treatment of a msi-h cancer
|
|
WO2020165833A1
(en)
|
2019-02-15 |
2020-08-20 |
Novartis Ag |
3-(1-oxo-5-(piperidin-4-yl)isoindolin-2-yl)piperidine-2,6-dione derivatives and uses thereof
|
|
AU2020222346B2
(en)
|
2019-02-15 |
2021-12-09 |
Novartis Ag |
Substituted 3-(1-oxoisoindolin-2-yl)piperidine-2,6-dione derivatives and uses thereof
|
|
KR20210130189A
(ko)
|
2019-02-20 |
2021-10-29 |
프레드 헛친슨 켄서 리서치 센터 |
Ras 신항원에 특이적인 결합 단백질 및 이의 용도
|
|
WO2020172658A1
(en)
|
2019-02-24 |
2020-08-27 |
Bristol-Myers Squibb Company |
Methods of isolating a protein
|
|
CN113784978B
(zh)
|
2019-03-11 |
2025-07-25 |
弗雷德哈钦森癌症中心 |
高亲合力wt1 t细胞受体及其用途
|
|
WO2020227159A2
(en)
|
2019-05-03 |
2020-11-12 |
Flagship Pioneering Innovations V, Inc. |
Methods of modulating immune activity
|
|
EP3973274A1
(en)
|
2019-05-23 |
2022-03-30 |
Bristol-Myers Squibb Company |
Methods of monitoring cell culture media
|
|
JP7737978B2
(ja)
|
2019-08-20 |
2025-09-11 |
フレッド ハッチンソン キャンサー センター |
Ｗｔ－１に特異的なｔ細胞免疫療法
|
|
AU2020336980B2
(en)
|
2019-08-29 |
2025-07-10 |
Vir Biotechnology, Inc. |
Antibody compositions and methods for treating hepatitis B virus infection
|
|
JP2022548881A
(ja)
|
2019-09-18 |
2022-11-22 |
ノバルティス アーゲー |
Ｅｎｔｐｄ２抗体、組合せ療法並びに抗体及び組合せ療法を使用する方法
|
|
EP4031575A1
(en)
|
2019-09-19 |
2022-07-27 |
Bristol-Myers Squibb Company |
Antibodies binding to vista at acidic ph
|
|
CN114786679A
(zh)
|
2019-10-21 |
2022-07-22 |
诺华股份有限公司 |
具有维奈托克和tim-3抑制剂的组合疗法
|
|
JP2022553306A
(ja)
|
2019-10-21 |
2022-12-22 |
ノバルティス アーゲー |
Ｔｉｍ－３阻害剤およびその使用
|
|
US20230114107A1
(en)
|
2019-12-17 |
2023-04-13 |
Flagship Pioneering Innovations V, Inc. |
Combination anti-cancer therapies with inducers of iron-dependent cellular disassembly
|
|
CN115175937A
(zh)
|
2019-12-20 |
2022-10-11 |
诺华股份有限公司 |
用于治疗骨髓纤维化和骨髓增生异常综合征的抗TIM-3抗体MBG453和抗TGF-β抗体NIS793与或不与地西他滨或抗PD-1抗体斯巴达珠单抗的组合
|
|
CN114901695A
(zh)
*
|
2020-01-02 |
2022-08-12 |
南京金斯瑞生物科技有限公司 |
抗gitr抗体及其用途
|
|
KR20220128389A
(ko)
|
2020-01-17 |
2022-09-20 |
노파르티스 아게 |
골수이형성 증후군 또는 만성 골수단핵구성 백혈병을 치료하는데 사용하기 위한 tim-3 억제제 및 저메틸화제를 포함하는 조합물
|
|
IL296043A
(en)
|
2020-03-06 |
2022-10-01 |
Regeneron Pharma |
Anti-gitro antibodies and their uses
|
|
JPWO2021225159A1
(cg-RX-API-DMAC7.html)
*
|
2020-05-08 |
2021-11-11 |
|
|
|
KR20230024967A
(ko)
|
2020-06-11 |
2023-02-21 |
노파르티스 아게 |
Zbtb32 억제제 및 이의 용도
|
|
CA3182346A1
(en)
|
2020-06-23 |
2021-12-30 |
Novartis Ag |
Dosing regimen comprising 3-(1-oxoisoindolin-2-yl)piperidine-2,6-dione derivatives
|
|
KR20230042023A
(ko)
|
2020-06-24 |
2023-03-27 |
비르 바이오테크놀로지, 인코포레이티드 |
조작된 b형 간염 바이러스 중화 항체 및 이의 용도
|
|
CN111732658B
(zh)
*
|
2020-06-28 |
2022-04-26 |
英诺湖医药(杭州)有限公司 |
一组gitr单克隆抗体及其医药用途
|
|
CA3184366A1
(en)
|
2020-06-29 |
2022-01-06 |
Darby Rye Schmidt |
Viruses engineered to promote thanotransmission and their use in treating cancer
|
|
US20230271940A1
(en)
|
2020-08-03 |
2023-08-31 |
Novartis Ag |
Heteroaryl substituted 3-(1-oxoisoindolin-2-yl)piperidine-2,6-dione derivatives and uses thereof
|
|
EP4204020A1
(en)
|
2020-08-31 |
2023-07-05 |
Advanced Accelerator Applications International S.A. |
Method of treating psma-expressing cancers
|
|
US20230321285A1
(en)
|
2020-08-31 |
2023-10-12 |
Advanced Accelerator Applications International Sa |
Method of treating psma-expressing cancers
|
|
US20250018036A1
(en)
|
2020-09-24 |
2025-01-16 |
Fred Hutchinson Cancer Center |
Immunotherapy targeting sox2 antigens
|
|
WO2022066973A1
(en)
|
2020-09-24 |
2022-03-31 |
Fred Hutchinson Cancer Research Center |
Immunotherapy targeting pbk or oip5 antigens
|
|
US20230374064A1
(en)
|
2020-10-05 |
2023-11-23 |
Bristol-Myers Squibb Company |
Methods for concentrating proteins
|
|
TW202222841A
(zh)
|
2020-10-06 |
2022-06-16 |
福瑞德哈金森腫瘤研究中心 |
用於治療表現mage-a1之疾病的組成物及方法
|
|
US20240018248A1
(en)
|
2020-12-02 |
2024-01-18 |
Vib Vzw |
An ltbr agonist in combination therapy against cancer
|
|
WO2022132836A2
(en)
|
2020-12-14 |
2022-06-23 |
Fred Hutchinson Cancer Research Center |
Compositions and methods for cellular immunotherapy
|
|
WO2022164805A1
(en)
|
2021-01-26 |
2022-08-04 |
Vir Biotechnology, Inc. |
Compositions and methods for treating hepatitis b virus infection
|
|
CA3214085A1
(en)
|
2021-03-31 |
2022-10-06 |
Darby Rye Schmidt |
Thanotransmission polypeptides and their use in treating cancer
|
|
TW202304979A
(zh)
|
2021-04-07 |
2023-02-01 |
瑞士商諾華公司 |
抗ＴＧＦβ抗體及其他治療劑用於治療增殖性疾病之用途
|
|
AR125874A1
(es)
|
2021-05-18 |
2023-08-23 |
Novartis Ag |
Terapias de combinación
|
|
CA3224374A1
(en)
|
2021-06-29 |
2023-01-05 |
Flagship Pioneering Innovations V, Inc. |
Immune cells engineered to promote thanotransmission and uses thereof
|
|
WO2023288281A2
(en)
|
2021-07-15 |
2023-01-19 |
Fred Hutchinson Cancer Center |
Chimeric polypeptides
|
|
KR20240156411A
(ko)
|
2022-03-09 |
2024-10-29 |
브리스톨-마이어스 스큅 컴퍼니 |
치료 단백질의 일시적 발현
|
|
EP4493195A1
(en)
|
2022-03-15 |
2025-01-22 |
Compugen Ltd. |
Il-18bp antagonist antibodies and their use in monotherapy and combination therapy in the treatment of cancer
|
|
WO2023215725A1
(en)
|
2022-05-02 |
2023-11-09 |
Fred Hutchinson Cancer Center |
Compositions and methods for cellular immunotherapy
|
|
WO2023230439A1
(en)
|
2022-05-23 |
2023-11-30 |
Vir Biotechnology, Inc. |
Fc-engineered hepatitis b virus neutralizing antibodies and uses thereof
|
|
WO2024077191A1
(en)
|
2022-10-05 |
2024-04-11 |
Flagship Pioneering Innovations V, Inc. |
Nucleic acid molecules encoding trif and additionalpolypeptides and their use in treating cancer
|
|
US20240269251A1
(en)
|
2023-01-09 |
2024-08-15 |
Flagship Pioneering Innovations V, Inc. |
Genetic switches and their use in treating cancer
|
|
TW202515608A
(zh)
|
2023-06-26 |
2025-04-16 |
以色列商坎布根有限公司 |
Ｉｌ—１８ｂｐ拮抗抗體及其於癌症治療之單一療法及組合療法的用途
|
|
WO2025081123A1
(en)
|
2023-10-12 |
2025-04-17 |
Fred Hutchinson Cancer Center |
Methods and compositions for improving t cell immunotherapy
|
|
WO2025101820A1
(en)
|
2023-11-08 |
2025-05-15 |
Fred Hutchinson Cancer Center |
Compositions and methods for cellular immunotherapy
|
|
WO2025245169A1
(en)
|
2024-05-21 |
2025-11-27 |
Fred Hutchinson Cancer Center |
Immunotherapy cells equipped with a collagen-targeting payload
|